Influence of Disease Modifying Treatment, Severe Acute Respiratory Syndrome Coronavirus 2 Variants and Vaccination on Coronavirus Disease 2019 Risk and Outcome in Multiple Sclerosis and Neuromyelitis Optica
暂无分享,去创建一个
[1] S. Saffari,et al. COVID-19 infection after SARS-CoV-2 mRNA vaccination in Multiple Sclerosis, AQP4-antibody NMOSD and MOGAD patients during the Omicron subvariant BA.1/2 wave in Singapore , 2023, Journal of Neurology.
[2] A. Haghdoost,et al. Multiple sclerosis and COVID-19: A retrospective study in Iran , 2023, PloS one.
[3] Ning Liu,et al. Outcome of COVID-19 Infection in Patients With Multiple Sclerosis Who Received Disease-Modifying Therapies: A Systematic Review and Meta-Analysis , 2023, Journal of clinical neurology.
[4] J. Kalina,et al. COVID-19 Vaccine Response in People with Multiple Sclerosis Treated with Dimethyl Fumarate, Diroximel Fumarate, Natalizumab, Ocrelizumab, or Interferon Beta Therapy , 2023, Neurology and Therapy.
[5] Shreena Desai,et al. A retrospective evaluation of seroconversion after COVID-19 during the early Omicron wave in fully vaccinated multiple sclerosis patients receiving anti-CD20 therapies , 2023, Multiple Sclerosis and Related Disorders.
[6] A. Bertozzi,et al. Safety and effectiveness of the booster dose of mRNA COVID-19 vaccines in people with multiple sclerosis: A monocentric experience , 2023, Multiple Sclerosis and Related Disorders.
[7] E. Butler,et al. COVID-19 Vaccine Status, Intent, Hesitancy, and Disease-Related Beliefs in People with Multiple Sclerosis , 2023, Vaccines.
[8] P. Dillon,et al. Electronic health record data for assessing risk of hospitalization for COVID-19: Methodological considerations applied to multiple sclerosis , 2023, Multiple Sclerosis and Related Disorders.
[9] A. ten Brinke,et al. SARS-CoV-2 omicron breakthrough infections in patients with multiple sclerosis , 2022, Journal of Neurology, Neurosurgery, and Psychiatry.
[10] S. Zamvil,et al. Longitudinal adaptive immune responses following sequential SARS-CoV-2 vaccinations in MS patients on anti-CD20 therapies and sphingosine-1-phosphate receptor modulators , 2022, Multiple Sclerosis and Related Disorders.
[11] E. Bernasconi,et al. Longitudinal Postvaccine SARS-CoV-2 Immunoglobulin G Titers, Memory B-Cell Responses, and Risk of COVID-19 in Multiple Sclerosis Over 1 Year , 2022, Neurology: Neuroimmunology & Neuroinflammation.
[12] S. Paybast,et al. Characteristics and management of multiple sclerosis patients during the Omicron era: is there a concern about the MS course in the face of the new variant of COVID-19? , 2022, Neurological Sciences.
[13] K. Longo,et al. Humoral efficacy of the third SARS-CoV-2 vaccine dose in Multiple Sclerosis subjects undergoing different disease-modifying therapies , 2022, Multiple Sclerosis and Related Disorders.
[14] V. Prčkovska,et al. Updated Results of the COVID-19 in MS Global Data Sharing Initiative , 2022, Neurology® Neuroimmunology & Neuroinflammation.
[15] V. Corman,et al. Humoral immune responses remain quantitatively impaired but improve qualitatively in anti-CD20-treated patients with multiple sclerosis after three or four COVID-19 vaccinations , 2022, medRxiv.
[16] H. Weiner,et al. Humoral response to COVID-19 vaccination in MS patients on disease modifying therapy: Immune profiles and clinical outcomes , 2022, Multiple Sclerosis and Related Disorders.
[17] M. Ulivelli,et al. Breakthrough SARS-CoV-2 infections after COVID-19 mRNA vaccination in MS patients on disease modifying therapies during the Delta and the Omicron waves in Italy , 2022, eBioMedicine.
[18] B. Weinstock-Guttman,et al. COVID-19 Vaccination in Multiple Sclerosis and Inflammatory Diseases: Effects from Disease-Modifying Therapy, Long-Term Seroprevalence and Breakthrough Infections , 2022, Vaccines.
[19] C. Rapôso,et al. Severe Acute Respiratory Syndrome Coronavirus 2 Third Vaccine Immune Response in Multiple Sclerosis Patients Treated with Ocrelizumab , 2022, Annals of Neurology.
[20] M. Exline,et al. Clinical severity of, and effectiveness of mRNA vaccines against, covid-19 from omicron, delta, and alpha SARS-CoV-2 variants in the United States: prospective observational study , 2022, BMJ.
[21] Young-A. Heo. Sotrovimab , 2022, Drugs.
[22] M. Etemadifar,et al. Multiple sclerosis disease-modifying therapies and COVID-19 vaccines: a practical review and meta-analysis , 2022, Journal of Neurology, Neurosurgery, and Psychiatry.
[23] A. Zabalza,et al. Risk factors of severe COVID-19 in people with multiple sclerosis : A systematic review and meta-analysis , 2021, Revue Neurologique.
[24] A. Achiron,et al. Humoral immune response in multiple sclerosis patients following PfizerBNT162b2 COVID19 vaccination: Up to 6 months cross-sectional study , 2021, Journal of Neuroimmunology.
[25] G. Comi,et al. Associations of Disease-Modifying Therapies With COVID-19 Severity in Multiple Sclerosis , 2021, Neurology.
[26] Jeffrey A. Cohen,et al. Clinical features and outcomes of COVID-19 despite SARS-CoV-2 vaccination in people with multiple sclerosis , 2021, Multiple sclerosis journal - experimental, translational and clinical.
[27] G. Disanto,et al. Association of Disease-Modifying Treatment and Anti-CD20 Infusion Timing With Humoral Response to 2 SARS-CoV-2 Vaccines in Patients With Multiple Sclerosis. , 2021, JAMA neurology.
[28] K. Schmierer,et al. COVID‐19 Vaccine Response in People with Multiple Sclerosis , 2021, medRxiv.
[29] M. Sahraian,et al. The prevalence of COVID-19 infection in patients with multiple sclerosis (MS): a systematic review and meta-analysis , 2021, Neurological Sciences.
[30] J. Mascola,et al. Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine , 2020, The New England journal of medicine.
[31] P. Dormitzer,et al. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine , 2020, The New England journal of medicine.
[32] David H. Miller,et al. Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria , 2017, The Lancet Neurology.
[33] A. Traboulsee,et al. International consensus diagnostic criteria for neuromyelitis optica spectrum disorders , 2015, Neurology.
[34] A. Filouš. [Diagnosis of multiple sclerosis]. , 1989, Ceskoslovenska neurologie a neurochirurgie.
[35] J. Kurtzke. Rating neurologic impairment in multiple sclerosis , 1983, Neurology.